Rubraca (rucaparib tablets – pharmaand GmbH) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has a BRCA mutation or PALB2 mutation
• Patient has tried platinum-based chemotherapy
• Patient has not had disease progression following the most recent platinum-based chemotherapy

Approval duration

1 year